Pressure BioSciences, Inc. · OTC:PBIO
Pressure BioSciences — FSXinterlinked Investor Conference 2014
16 slides from Pressure BioSciences's conference presentation, Oct 31, 2014
Slide 1: Investor Presentation: Pressure BioSciences, Inc.
Investor Presentation Pressure BioSciences, Inc. (OTCQB: PBIO) Discovery Starts with Sample Preparation™ FSXinterlinked Investor Conference Dove Mountain, AZ October 29-31, 2014 Richard T. Schumacher PBI President, CEO
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward looking statements that reflect management's current views and opinions as to the status of the Company’s products, technology and other future events and operations. These statements are neither a promise nor guarantee, but involve ri
Slide 3: Company Overview
Company Overview (OTCQB: PBIO) ¢« QFT Staff; Near Boston,MA; Publicly Traded (OTCQB: PBI) ¢ Market Cap (fully diluted): $10 Million « 24 Patents: Pressure Cycling Technology (“PCT”) Platform * Develop, Mfg, & Sell PCT-based Instruments & Consumables ¢ Initial Focus in Sample Preparation for the Rese
Slide 4: Experienced Senior Management & Board
perienced Senior Management & Board Management + Mr.Richard T. Schumacher, President & CEO Boston Biomedica (CEO, Founder); Panacos Pharma (President, Co-founder); Trinity Biotech (Founding Group); CBR Labs (Gen’ | Mgr) - Harvard Medical School + Dr. Edmund V. Ting, Senior Vice President of Engineer
Slide 5: Primary Sample Preparation for Biomolecular Analysis: Cell Lysis
Primary Sample Preparation for Biomolecular Analysis: Cell Lysis
Slide 6: Value Proposition: PCT-based biological sample preparation
Value Proposition: PCT-based biological sample preparation + Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”) is Crucial to the Discovery of New Biomarkers + The Quality of Biomolecule Analysis Depends Significantly on the Quality of the Preparation of the Sample to be Analyzed * Biological
Slide 7: Biomarker/Forensics Market: Estimated Size
Biomarker/Forensics Market: Estimated Size Estimated Market * Genomics (DNA/RNA) $7.1B in 2015 > * Next Gen Sequencing (DNA) $2.7B in 2017¢ * Mass Spectrometry (Proteins $2.7B in 201144 * Forensic Tools and Products (DNA) $17.7B in 2019 © * Sample Prep for all OMICS: $8.4B in 2016 * 500,000 Scientis
Slide 8: Selected Marquee Customers (150)
Selected Marquee Customers (150) Cr Ly, Eee HARVARD tt EA MEDICAL SCHOOL MONSANTO ¥ Eom National Institutes of Health ipt U.S.ARMY
Slide 9: PCT Focus Area: Biomarker Discovery & Forensics
PCT Focus Area: Biomarker Discovery & Forensics Biomarker Discovery: Cancer, Heart Disease, Stroke, Inf. Diseases, Etc. Dr. Andreas Huhmer - Thermo Fisher Scientific Dr. Michael Alterman — Tumor Vaccines and Biotechnology Branch, CBER, FDA Dr. Alexander Ivanov — Harvard School of Public Health Dr. J
Slide 10: PCT Sample Preparation System
PCT Sample Preparation System = =n Ci — Barocycler™ wi NEP2320 Barocycler™ NEP3229 PULSE Tube PCT-dependent Kits PBI MicroTubes 1
Slide 11: Automated liquid handling helps ensure accuracy and reproducibility
Automated liquid handling helps ensure accuracy and reproducibility, eliminates repetitive tasks, and frees personnel for other activities.
Slide 12: The Solution (4 years in the making)
he Solution (4 years in the making, ¢ Initial Application: — High pressure digestion ¢ Consumable: — Proprietary 8-well strips « Number of Samples: — 48 samples ¢ User Control: — Easy to use touch screen — LabView Software 15
Slide 13: The Future (is now)
The Future (is now) PBI 16
Slide 14: Professor Wayne L. Hubbell
Professor Wayne L. Hubbell Prof Wayne Hubbell Dr. Jennifer Van Eyk Mr. David Weild Distinguished Prof: UCLA School of Medicine Member, Nat’l Academy of Sciences Gold Medal, International EPR Society Research: Structure & Function Proteins Prof of Medicine, Cedars-Sinai Med. Ctr. Director, Barbara St
Slide 15: Sept Completion of the 1st Phase of Barozyme HT48 Commercialization Plan
Sept 19 Completion of the 1st Phase of Barozyme HT48 Commercialization Plan — first install expected in Oct 2014 Oct 1% PBI Invited to Speak at Warsaw Stock Exchange. $100B (US) Available Through Grants. Non-dilutive. Oct 20% Announced Partnership with Powertech Technology Company to Develop China M
Slide 16: Key Investment Highlights
Key Investment Highlights + Pressure Cycling Technology (PCT): Powerful, Enabling, Patented Proven Technology: ~ 250 Installations in ~150 Marquee Laboratories Experienced Management Team and Board of Directors Large Market Opportunity (est. $6 Billion; 80k Labs) Closed $3M PIPE (Dec 2013 to June 20
Pressure Biosciences — FSXinterlinked Investor Conference 2014 on 6ix